{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:36:30Z","timestamp":1791894990322,"version":"4.3.4"},"reference-count":101,"publisher":"American Society for Microbiology","issue":"6","license":[{"start":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T00:00:00Z","timestamp":1647993600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1128\/ASMCopyrightv2"},{"start":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T00:00:00Z","timestamp":1647993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["IMMUNOMOD"],"award-info":[{"award-number":["IMMUNOMOD"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["Restrict SARS-CoV-2"],"award-info":[{"award-number":["Restrict SARS-CoV-2"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["CRC 1279"],"award-info":[{"award-number":["CRC 1279"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SPP 1923"],"award-info":[{"award-number":["SPP 1923"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["KM 5\/1-1"],"award-info":[{"award-number":["KM 5\/1-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["J Virol"],"published-print":{"date-parts":[[2022,3,23]]},"abstract":"<jats:p>Emerging strains of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the coronavirus disease 2019 (COVID-19) pandemic, that show increased transmission fitness and\/or immune evasion are classified as \u201cvariants of concern\u201d (VOCs). Recently, a SARS-CoV-2 variant first identified in November 2021 in South Africa has been recognized as a fifth VOC, termed \u201cOmicron.\u201d What makes this VOC so alarming is the high number of changes, especially in the viral Spike protein, and accumulating evidence for increased transmission efficiency and escape from neutralizing antibodies.<\/jats:p>","DOI":"10.1128\/jvi.02077-21","type":"journal-article","created":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T16:54:47Z","timestamp":1646067287000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":192,"title":["Omicron: What Makes the Latest SARS-CoV-2 Variant of Concern So Concerning?"],"prefix":"10.1128","volume":"96","author":[{"given":"Christoph","family":"Jung","sequence":"first","affiliation":[{"name":"Institute of Electrochemistry, Ulm University, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorota","family":"Kmiec","sequence":"additional","affiliation":[{"name":"Institute of Molecular Virology, Ulm University Medical Center, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lennart","family":"Koepke","sequence":"additional","affiliation":[{"name":"Institute of Molecular Virology, Ulm University Medical Center, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Zech","sequence":"additional","affiliation":[{"name":"Institute of Molecular Virology, Ulm University Medical Center, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timo","family":"Jacob","sequence":"additional","affiliation":[{"name":"Institute of Electrochemistry, Ulm University, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin M. J.","family":"Sparrer","sequence":"additional","affiliation":[{"name":"Institute of Molecular Virology, Ulm University Medical Center, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7052-2360","authenticated-orcid":true,"given":"Frank","family":"Kirchhoff","sequence":"additional","affiliation":[{"name":"Institute of Molecular Virology, Ulm University Medical Center, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","unstructured":"World Health Organization. 2021. Classification of Omicron (B.1.1.529): SARS-CoV-2 variant of concern. https:\/\/www.who.int\/news\/item\/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-00480-0"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-021-03552-w"},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","unstructured":"Grabowski F Kocha\u0144czyk M Lipniacki T. 2022. The spread of SARS-CoV-2 variant Omicron with the doubling time of 2.0\u20133.3 days can be explained by immune evasion. medRxiv. https:\/\/www.medrxiv.org\/content\/10.1101\/2021.12.08.21267494v2.","DOI":"10.1101\/2021.12.08.21267494"},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","unstructured":"Bai Y Du Z Xu M Wang L Wu P Lau E Cowling BJ Meyers LA. 2021. International risk of SARS-CoV-2 Omicron variant importations originating in South Africa. medRxiv. https:\/\/www.medrxiv.org\/content\/10.1101\/2021.12.07.21267410v1.","DOI":"10.1101\/2021.12.07.21267410"},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","unstructured":"Pulliam JRC van Schalkwyk C Govender N von Gottberg A Cohen C Groome MJ Dushoff J Mlisana K Moultrie H. 2021. Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa. medRxiv. https:\/\/www.medrxiv.org\/content\/10.1101\/2021.11.11.21266068v2.","DOI":"10.1101\/2021.11.11.21266068"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2021.26.50.2101146"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2021.26.50.2101147"},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","unstructured":"Andrews N Stowe J Kirsebom F Toffa S Rickeard T Gallagher E Gower C Kall M Groves N O\u2019Connell A-M Simons D Blomquist PB Zaidi A Nash S Aziz NIBA Thelwall S Dabrera G Myers R Amirthalingam G Gharbia S Barrett JC Elson R Ladhani SN Ferguson N Zambon M Campbell CN Brown K Hopkins S Chand M Ramsay M Bernal JL. 2021. Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern. medRxiv. https:\/\/www.medrxiv.org\/content\/10.1101\/2021.12.14.21267615v1.","DOI":"10.1101\/2021.12.14.21267615"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab1041"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2021.2017757"},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","unstructured":"Wilhelm A Widera M Grikscheit K Toptan T Schenk B Pallas C Metzler M Kohmer N Hoehl S Helfritz FA Wolf T Goetsch U Ciesek S. 2021. Reduced neutralization of SARS-CoV-2 Omicron variant by vaccine sera and monoclonal antibodies. medRxiv. https:\/\/www.medrxiv.org\/content\/10.1101\/2021.12.07.21267432v4.","DOI":"10.1101\/2021.12.07.21267432"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03777-9"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.12.032"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04387-1"},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","unstructured":"Basile K Rockett RJ McPhie K Fennell M Johnson-Mackinnon J Agius JE Fong W Rahman H Ko D Donavan L Hueston L Lam C Arnott A Chen SC-A Maddocks S O\u2019Sullivan MV Dwyer DE Sintchenko V Kok J. 2021. Improved neutralization of the SARS-CoV-2 Omicron variant after Pfizer-BioNTech BNT162b2 COVID-19 vaccine boosting. bioRxiv. https:\/\/www.biorxiv.org\/content\/10.1101\/2021.12.12.472252v1.","DOI":"10.1101\/2021.12.12.472252"},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","unstructured":"Garcia-Beltran WF Denis KJS Hoelzemer A Lam EC Nitido AD Sheehan ML Berrios C Ofoman O Chang CC Hauser BM Feldman J Gregory DJ Poznansky MC Schmidt AG Iafrate AJ Naranbhai V Balazs AB. 2021. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. medRxiv. https:\/\/www.medrxiv.org\/content\/10.1101\/2021.12.14.21267755v1.","DOI":"10.2139\/ssrn.3985605"},{"key":"e_1_3_2_19_2","doi-asserted-by":"crossref","unstructured":"Gruell H Vanshylla K Tober-Lau P Hillus D Schommers P Lehmann C Kurth F Sander LE Klein F. 2021. mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant. medRxiv. https:\/\/www.medrxiv.org\/content\/10.1101\/2021.12.14.21267769v1.","DOI":"10.21203\/rs.3.rs-1168453\/v1"},{"key":"e_1_3_2_20_2","unstructured":"Cong Z Evans JP Qu P Faraone J Zheng Y-M Carlin C Bednash JS Zhou T Lozanski G Mallampalli R Saif LJ Oltz EM Mohler P Xu K Gumina RJ Liu S-L. 2021. Neutralization and stability of SARS-CoV-2 Omicron variant. bioRxiv. https:\/\/www.biorxiv.org\/content\/10.1101\/2021.12.16.472934v1."},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","unstructured":"Redd AD Nardin A Kared H Bloch EM Abel B Pekosz A Laeyendecker O Fehlings M Quinn TC Tobian AA. 2021. Minimal cross-over between mutations associated with Omicron variant of SARS-CoV-2 and CD8+ T cell epitopes identified in COVID-19 convalescent individuals. bioRxiv. 10.1101\/2021.12.06.471446.","DOI":"10.1101\/2021.12.06.471446"},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","unstructured":"Ahmed SF Quadeer AA McKay MR. 2021. SARS-CoV-2 T cell responses are expected to remain robust against Omicron. bioRxiv. https:\/\/www.biorxiv.org\/content\/10.1101\/2021.12.12.472315v1.","DOI":"10.1101\/2021.12.12.472315"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01700-x"},{"key":"e_1_3_2_24_2","doi-asserted-by":"crossref","unstructured":"Keeton R Tincho MB Ngomti A Baguma R Benede N Suzuki A Khan K Cele S Bernstein M Karim F Madzorera SV Moyo-Gwete T Mennen M Skelem S Adriaanse M Mutithu D Aremu O Stek C du Bruyn E Mescht MAVD de Beer Z de Villiers TR Bodenstein A van den Berg G Mendes A Strydom A Venter M Grifoni A Weiskopf D Sette A Wilkinson RJ Bekker L-G Gray G Ueckermann V Rossouw T Boswell MT Bihman J Moore PL Sigal A Ntusi NAB Burgers WA Riou C. 2021. SARS-CoV-2 spike T cell responses induced upon vaccination or infection remain robust against Omicron. medRxiv. https:\/\/www.medrxiv.org\/content\/10.1101\/2021.12.26.21268380v1.","DOI":"10.1101\/2021.12.26.21268380"},{"key":"e_1_3_2_25_2","doi-asserted-by":"crossref","unstructured":"Yuan S Ye Z-W Liang R Tang K Zhang AJ Lu G Ong CP Poon VK-M Chan CC-S Mok BW-Y Qin Z Xie Y Sun H Tsang JO-L Yuen TT-T Chik KK-H Chan CC-Y Cai J-P Luo C Lu L Yip CC-Y Chu H To KK-W Chen H Jin D-Y Yuen K-Y Chan JF-W. 2022. The SARS-CoV-2 Omicron (B.1.1.529) variant exhibits altered pathogenicity transmissibility and fitness in the golden Syrian hamster model. bioRxiv. https:\/\/www.biorxiv.org\/content\/10.1101\/2022.01.12.476031v1.","DOI":"10.1101\/2022.01.12.476031"},{"key":"e_1_3_2_26_2","doi-asserted-by":"crossref","unstructured":"Vihta K-D Pouwels KB Peto TE Pritchard E House T Studley R Rourke E Cook D Diamond I Crook D Matthews PC Stoesser N Eyre DW Walker AS Team C-19 IS. 2022. Omicron-associated changes in SARS-CoV-2 symptoms in the United Kingdom. medRxiv. https:\/\/www.medrxiv.org\/content\/10.1101\/2022.01.18.22269082v1.","DOI":"10.1101\/2022.01.18.22269082"},{"key":"e_1_3_2_27_2","doi-asserted-by":"crossref","unstructured":"Garrett N Tapley A Andriesen J Seocharan I Fisher LH Bunts L Espy N Wallis CL Randhawa AK Ketter N Yacovone M Goga A Bekker L-G Gray GE Corey L. 2022. High rate of asymptomatic carriage associated with variant strain Omicron. medRxiv. https:\/\/www.medrxiv.org\/content\/10.1101\/2021.12.20.21268130v2.","DOI":"10.1101\/2021.12.20.21268130"},{"key":"e_1_3_2_28_2","doi-asserted-by":"crossref","unstructured":"Christensen PA Olsen RJ Long SW Snehal R Davis JJ Saavedra MO Reppond K Shyer MN Cambric J Gadd R Thakur RM Batajoo A Mangham R Pena S Trinh T Kinskey JC Williams G Olson R Gollihar J Musser JM. 2022. Signals of significantly increased vaccine breakthrough decreased hospitalization rates and less severe disease in patients with COVID-19 caused by the Omicron variant of SARS-CoV-2 in Houston Texas. medRxiv. https:\/\/www.medrxiv.org\/content\/10.1101\/2021.12.30.21268560v3.","DOI":"10.1101\/2021.12.30.21268560"},{"key":"e_1_3_2_29_2","doi-asserted-by":"crossref","unstructured":"Wolter N Jassat W Walaza S Welch R Moultrie H Groome M Amoako DG Everatt J Bhiman JN Scheepers C Tebeila N Chiwandire N du Plessis M Govender N Ismail A Glass A Mlisana K Stevens W Treurnicht FK Makatini Z Hsiao N Parboosing R Wadula J Hussey H Davies M-A Boulle A von Gottberg A Cohen C. 2021. Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South Africa. medRxiv. https:\/\/www.medrxiv.org\/content\/10.1101\/2021.12.21.21268116v1.","DOI":"10.1101\/2021.12.21.21268116"},{"key":"e_1_3_2_30_2","doi-asserted-by":"crossref","unstructured":"Bentley EG Kirby A Sharma P Kipar A Mega DF Bramwell C Penrice-Randal R Prince T Brown JC Zhou J Screaton GR Barclay WS Owen A Hiscox JA Stewart JP. 2021. SARS-CoV-2 Omicron-B.1.1.529 variant leads to less severe disease than Pango B and Delta variants strains in a mouse model of severe COVID-19. bioRxiv. https:\/\/www.biorxiv.org\/content\/10.1101\/2021.12.26.474085v2.","DOI":"10.1101\/2021.12.26.474085"},{"key":"e_1_3_2_31_2","doi-asserted-by":"crossref","unstructured":"Diamond M Halfmann P Maemura T Iwatsuki-Horimoto K Iida S Kiso M Scheaffer S Darling T Joshi A Loeber S Foster S Ying B Whitener B Floyd K Ujie M Nakajima N Ito M Wright R Uraki R Li R Sakai Y Liu Y Larson D Osorio J Hernandez-Ortiz J \u010ciuoderis K Florek K Patel M Bateman A Odle A Wong L-Y Wang Z Edara VV Chong Z Thackray L Ueki H Yamayoshi S Imai M Perlman S Webby R Seder R Suthar M Garcia-Sastre A Schotsaert M Suzuki T Boon A Kawaoka Y Douek D Moliva J Sullivan N Gagne M Ransier A Case J Jeevan T Franks J Fabrizio T DeBeauchamp J Kercher L Seiler P Singh G Warang P Gonzalez-Reiche AS Sordillo E van Bakel H Simon V. 2022. The SARS-CoV-2 B.1.1.529 Omicron virus causes attenuated infection and disease in mice and hamsters. Res Sq. https:\/\/www.researchsquare.com\/article\/rs-1211792\/v1.","DOI":"10.21203\/rs.3.rs-1211792\/v1"},{"key":"e_1_3_2_32_2","doi-asserted-by":"crossref","unstructured":"McMahan K Giffin V Tostanoski LH Chung B Siamatu M Suthar MS Halfmann P Kawaoka Y Piedra-Mora C Martinot AJ Kar S Andersen H Lewis MG Barouch DH. 2022. Reduced pathogenicity of the SARS-CoV-2 Omicron variant in hamsters. bioRxiv. https:\/\/www.biorxiv.org\/content\/10.1101\/2022.01.02.474743v1.","DOI":"10.1101\/2022.01.02.474743"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2006.01.017"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/febs.15815"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000896"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2020.07.027"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12977-015-0148-6"},{"key":"e_1_3_2_38_2","doi-asserted-by":"crossref","unstructured":"Bansal K Kumar S. 2021. Mutational cascade of SARS-CoV-2 leading to evolution and emergence of omicron variant. bioRxiv. https:\/\/www.biorxiv.org\/content\/10.1101\/2021.12.06.471389v1.","DOI":"10.1101\/2021.12.06.471389"},{"key":"e_1_3_2_39_2","doi-asserted-by":"crossref","unstructured":"Nchioua R Schundner A Klute S Noettger S Zech F Koepke L Graf A Krebs S Blum H Kmiec D Frick M Kirchhoff F Sparrer KMJ. 2021. The Delta variant of SARS-CoV-2 maintains high sensitivity to interferons in human lung cells. bioRxiv. https:\/\/www.biorxiv.org\/content\/10.1101\/2021.11.16.468777v1.","DOI":"10.1101\/2021.11.16.468777"},{"key":"e_1_3_2_40_2","doi-asserted-by":"crossref","unstructured":"Thorne LG Bouhaddou M Reuschl A-K Zuliani-Alvarez L Polacco B Pelin A Batra J Whelan MVX Ummadi M Rojc A Turner J Obernier K Braberg H Soucheray M Richards A Chen K-H Harjai B Memon D Hosmillo M Hiatt J Jahun A Goodfellow IG Fabius JM Shokat K Jura N Verba K Noursadeghi M Beltrao P Swaney DL Garcia-Sastre A Jolly C Towers GJ Krogan NJ. 2021. Evolution of enhanced innate immune evasion by the SARS-CoV-2 B.1.1.7 UK variant. bioRxiv. https:\/\/www.biorxiv.org\/content\/10.1101\/2021.06.06.446826v1.","DOI":"10.1101\/2021.06.06.446826"},{"key":"e_1_3_2_41_2","doi-asserted-by":"crossref","unstructured":"Karim F Moosa MYS Gosnell BI Cele S Giandhari J Pillay S Tegally H Wilkinson E San JE Msomi N Mlisana K Khan K Bernstein M Manickchund N Singh L Ramphal U COMMIT-KZN Team Hanekom W Lessells RJ Sigal A de Oliveira T. 2021. Persistent SARS-CoV-2 infection and intra-host evolution in association with advanced HIV infection. medRxiv. https:\/\/www.medrxiv.org\/content\/10.1101\/2021.06.03.21258228v1.","DOI":"10.1101\/2021.06.03.21258228"},{"key":"e_1_3_2_42_2","doi-asserted-by":"crossref","unstructured":"Wei C Shan K-J Wang W Zhang S Huan Q Qian W. 2021. Evidence for a mouse origin of the SARS-CoV-2 Omicron variant. bioRxiv. https:\/\/www.biorxiv.org\/content\/10.1101\/2021.12.14.472632v1.","DOI":"10.1101\/2021.12.14.472632"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1080\/01652176.2021.1921311"},{"key":"e_1_3_2_44_2","doi-asserted-by":"crossref","unstructured":"Stone S Rothan HA Natekar JP Kumari P Sharma S Pathak H Arora K Aurani TT Kumar M. 2021. SARS-CoV-2 variants of concern infect the respiratory tract and induce inflammatory response in wild-type laboratory mice. bioRxiv. https:\/\/biorxiv.org\/cgi\/content\/short\/2021.09.29.462373.","DOI":"10.1101\/2021.09.29.462373"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103643"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibs.2016.05.001"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.3390\/v13030394"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1128\/mSphere.00408-20"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2020.10.092"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-24448-2"},{"key":"e_1_3_2_51_2","doi-asserted-by":"crossref","unstructured":"Chen X Kim K Calabrese P Wang S Qin C Rao Y Feng P. 2021. APOBEC-mediated editing of SARS-CoV-2 genomic RNA impacts viral replication and fitness. bioRxiv. https:\/\/www.biorxiv.org\/content\/10.1101\/2021.12.18.473309v1.","DOI":"10.1101\/2021.12.18.473309"},{"key":"e_1_3_2_52_2","doi-asserted-by":"crossref","unstructured":"Song Y He X Yang W Tang T Zhang R. 2021. ADAR mediated A-to-I RNA editing affects SARS-CoV-2 characteristics and fuels its evolution. bioRxiv. https:\/\/www.biorxiv.org\/content\/10.1101\/2021.07.22.453345v1.","DOI":"10.1101\/2021.07.22.453345"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature24039"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.01930-20"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109126"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.108234"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.02335-21"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03819-2"},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2020.03.058"},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2368-8"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2021.103353"},{"key":"e_1_3_2_62_2","doi-asserted-by":"crossref","unstructured":"Leary S Gaudieri S Parker MD Chopra A James I Pakala S Alves E John M Lindsey BB Keeley AJ Rowland-Jones SL Swanson MS Ostrov DA Bubenik JL Das S Sidney J Sette A COVID-19 Genomics UK (COG-UK) Consortium de Silva TI Phillips E Mallal S. 2021. Generation of a novel SARS-CoV-2 sub-genomic RNA due to the R203K\/G204R variant in nucleocapsid: homologous recombination has potential to change SARS-CoV-2 at both protein and RNA level. bioRxiv. https:\/\/www.biorxiv.org\/content\/10.1101\/2020.04.10.029454v4.","DOI":"10.1101\/2020.04.10.029454"},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-020-0688-y"},{"key":"e_1_3_2_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.02.058"},{"key":"e_1_3_2_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.02.052"},{"key":"e_1_3_2_66_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03925-1"},{"key":"e_1_3_2_67_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24817-y"},{"key":"e_1_3_2_68_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00558-8"},{"key":"e_1_3_2_69_2","doi-asserted-by":"crossref","unstructured":"Sarkar R Lo M Saha R Dutta S Chawla-Sarkar M. 2021. S glycoprotein diversity of the Omicron variant. medRxiv. https:\/\/www.medrxiv.org\/content\/10.1101\/2021.12.04.21267284v2.","DOI":"10.1101\/2021.12.04.21267284"},{"key":"e_1_3_2_70_2","doi-asserted-by":"crossref","unstructured":"Genovese L Zaccaria M Farzan M Johnson WE Momeni B. 2021. Investigating the mutational landscape of the SARS-CoV-2 Omicron variant via ab initio quantum mechanical modeling. bioRxiv. https:\/\/www.biorxiv.org\/content\/10.1101\/2021.12.01.470748v1.","DOI":"10.1101\/2021.12.01.470748"},{"key":"e_1_3_2_71_2","doi-asserted-by":"crossref","unstructured":"Zahradnik J Tuekprakhon A Ginn HM Duyvesteyn HME Bahar M Khan S Avinoam O Zhou D Nutalai R Supasa P Wang B Dejnirattisai W Liu C Dijokaite A Temperton N Mongkolsapaya J Fry EE Ren J Screaton GR Schreiber G Stuart DI. 2021. Receptor binding and escape from Beta antibody responses drive Omicron-B.1.1.529 evolution. bioRxiv. https:\/\/www.biorxiv.org\/content\/10.1101\/2021.12.03.471045v1.","DOI":"10.2139\/ssrn.3977262"},{"key":"e_1_3_2_72_2","doi-asserted-by":"crossref","unstructured":"Golcuk M Yildiz A Gur M. 2021. The Omicron variant increases the interactions of SARS-CoV-2 Spike glycoprotein with ACE2. bioRxiv. https:\/\/www.biorxiv.org\/content\/10.1101\/2021.12.06.471377v1.","DOI":"10.1101\/2021.12.06.471377"},{"key":"e_1_3_2_73_2","doi-asserted-by":"crossref","unstructured":"Shah M Woo HG. 2021. Omicron: a heavily mutated SARS-CoV-2 variant exhibits stronger binding to ACE2 and potently escape approved COVID-19 therapeutic antibodies. bioRxiv. https:\/\/www.biorxiv.org\/content\/10.1101\/2021.12.04.471200v1.","DOI":"10.1101\/2021.12.04.471200"},{"key":"e_1_3_2_74_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109292"},{"key":"e_1_3_2_75_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20789-7"},{"key":"e_1_3_2_76_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2020.06.020"},{"key":"e_1_3_2_77_2","doi-asserted-by":"crossref","unstructured":"Escalera A Gonzalez-Reiche AS Aslam S Mena I Pearl RL Laporte M Fossati A Rathnasinghe R Alshammary H van de Guchte A Bouhaddou M Kehrer T Zuliani-Alvarez L Meekins DA Balaraman V McDowell C Richt JA Bajic G Sordillo EM Krogan N Simon V Albrecht RA van Bakel H Garcia-Sastre A Aydillo T. 2021. SARS-CoV-2 variants of concern have acquired mutations associated with an increased spike cleavage. bioRxiv. https:\/\/www.biorxiv.org\/content\/10.1101\/2021.11.09.467693v1.","DOI":"10.1101\/2021.08.05.455290"},{"key":"e_1_3_2_78_2","doi-asserted-by":"crossref","unstructured":"Peacock TP Brown JC Zhou J Thakur N Newman J Kugathasan R Sukhova K Kaforou M Bailey D Barclay WS. 2022. The SARS-CoV-2 variant Omicron shows rapid replication in human primary nasal epithelial cultures and efficiently uses the endosomal route of entry. bioRxiv. https:\/\/www.biorxiv.org\/content\/10.1101\/2021.12.31.474653v1.","DOI":"10.1101\/2021.12.31.474653"},{"key":"e_1_3_2_79_2","doi-asserted-by":"crossref","unstructured":"Liu Y Liu J Johnson BA Xia H Ku Z Schindewolf C Widen SG An Z Weaver SC Menachery VD Xie X Shi P-Y. 2021. Delta spike P681R mutation enhances SARS-CoV-2 fitness over Alpha variant. bioRxiv. 10.1101\/2021.08.12.456173.","DOI":"10.1101\/2021.08.12.456173"},{"key":"e_1_3_2_80_2","doi-asserted-by":"crossref","unstructured":"Lista MJ Winstone H Wilson HD Dyer A Pickering S Galao RP Lorenzo GD Cowton VM Furnon W Suarez N Orton R Palmarini M Patel AH Snell L Nebbia G Swanson C Neil SJD. 2021. The P681H mutation in the Spike glycoprotein confers type I interferon resistance in the SARS-CoV-2 alpha (B.1.1.7) variant. bioRxiv. https:\/\/www.biorxiv.org\/content\/10.1101\/2021.11.09.467693v1.","DOI":"10.1101\/2021.11.09.467693"},{"key":"e_1_3_2_81_2","doi-asserted-by":"crossref","unstructured":"Wang Q Anang S Iketani S Guo Y Liu L Ho DD Sodroski JG. 2021. Functional properties of the spike glycoprotein of the emerging SARS-CoV-2 variant B.1.1.529. bioRxiv. https:\/\/www.biorxiv.org\/content\/10.1101\/2021.12.27.474288v1.","DOI":"10.1101\/2021.12.27.474288"},{"key":"e_1_3_2_82_2","doi-asserted-by":"crossref","unstructured":"Zaccaria M Genovese L Farzan M Dawson W Nakajima T Johnson W Momeni B. 2021. Anticipating future SARS-CoV-2 variants of concern through ab initio quantum mechanical modeling. bioRxiv. https:\/\/www.biorxiv.org\/content\/10.1101\/2021.11.25.470044v1.","DOI":"10.1101\/2021.11.25.470044"},{"key":"e_1_3_2_83_2","doi-asserted-by":"crossref","unstructured":"Mannar D Saville JW Zhu X Srivastava SS Berezuk AM Tuttle K Marquez C Sekirov I Subramaniam S. 2021. SARS-CoV-2 Omicron variant: ACE2 binding cryo-EM structure of Spike protein-ACE2 complex and antibody evasion. bioRxiv. https:\/\/www.biorxiv.org\/content\/10.1101\/2021.12.19.473380v1.","DOI":"10.1101\/2021.12.19.473380"},{"key":"e_1_3_2_84_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2022.01.006"},{"key":"e_1_3_2_85_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00863-2"},{"key":"e_1_3_2_86_2","doi-asserted-by":"crossref","unstructured":"Liu L Iketani S Guo Y Chan JF-W Wang M Liu L Luo Y Chu H Huang Y Nair MS Yu J Chik KK-H Yuen TT-T Yoon C To KK-W Chen H Yin MT Sobieszczyk ME Huang Y Wang HH Sheng Z Yuen K-Y Ho DD. 2021. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. bioRxiv. https:\/\/www.biorxiv.org\/content\/10.1101\/2021.12.14.472719v2.","DOI":"10.1101\/2021.12.14.472719"},{"key":"e_1_3_2_87_2","doi-asserted-by":"crossref","unstructured":"VanBlargan LA Errico JM Halfmann P Zost SJ Crowe JE Purcell LA Kawaoka Y Corti D Fremont DH Diamond M. 2021. An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by several therapeutic monoclonal antibodies. bioRxiv. https:\/\/www.biorxiv.org\/content\/10.1101\/2021.12.15.472828v1.","DOI":"10.21203\/rs.3.rs-1175516\/v1"},{"key":"e_1_3_2_88_2","doi-asserted-by":"crossref","unstructured":"Cameroni E Saliba C Bowen JE Rosen LE Culap K Pinto D Marco AD Zepeda SK di Iulio J Zatta F Kaiser H Noack J Farhat N Czudnochowski N Havenar-Daughton C Sprouse KR Dillen JR Powell AE Chen A Maher C Yin L Sun D Soriaga L Gustafsson C Franko NM Logue J Iqbal NT Mazzitelli I Geffner J Grifantini R Chu H Gori A Riva A Giannini O Ceschi A Ferrari P Franzetti-Pellanda A Garzoni C Hebner C Purcell LA Piccoli L Pizzuto MS Walls AC Telenti A Virgin HW Lanzavecchia A Veesler D Snell G Corti D. 2021. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. bioRxiv. https:\/\/www.biorxiv.org\/content\/10.1101\/2021.12.12.472269v1.","DOI":"10.1038\/d41586-021-03825-4"},{"key":"e_1_3_2_89_2","doi-asserted-by":"crossref","unstructured":"Aggarwal A Stella AO Walker G Akerman A Milogiannakis V Brilot F Amatayakul-Chantler S Roth N Coppola G Schofield P Jackson J Henry JY Mazigi O Langley D Lu Y Forster C McAllery S Mathivanan V Fichter C Hoppe AC Munier ML Jack H-M Cromer D Darley D Matthews G Christ D Khoury D Davenport M Rawlinson W Kelleher AD Turville S. 2021. SARS-CoV-2 Omicron: evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern. medRxiv. https:\/\/www.medrxiv.org\/content\/10.1101\/2021.12.14.21267772v1.","DOI":"10.1101\/2021.12.14.21267772"},{"key":"e_1_3_2_90_2","doi-asserted-by":"crossref","unstructured":"Xie X Cao Y Wang J Jian F Xiao T Song W Yisimayi A Li T Yu Y Wang Y Wang J Niu X Wang P An R Liang H Sun H Yang S Cui Q Liu S Du S Zhang Z Shao F Huang W Xiao J Wang Y Wang X Yang X Li Q Hao X Ronghua J. 2021. B.1.1.529 escapes the majority of SARS-CoV-2 neutralizing antibodies of diverse epitopes. Res Sq. https:\/\/www.researchsquare.com\/article\/rs-1148985\/v1.","DOI":"10.21203\/rs.3.rs-1148985\/v1"},{"key":"e_1_3_2_91_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04005-0"},{"key":"e_1_3_2_92_2","doi-asserted-by":"crossref","unstructured":"Vangeel L Chiu W Jonghe SD Maes P Slechten B Raymenants J Andr\u00e9 E Leyssen P Neyts J Jochmans D. 2022. Remdesivir molnupiravir and nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern. bioRxiv. https:\/\/www.biorxiv.org\/content\/10.1101\/2021.12.27.474275v2.","DOI":"10.1101\/2021.12.27.474275"},{"key":"e_1_3_2_93_2","doi-asserted-by":"crossref","unstructured":"Monteil V Stephanie D Klingstr\u00f6m J Th\u00e5lin C Kellner MJ Christ W Havervall S Mereiter S Knapp S Montserrat N Braunsfeld B Kozieradzki I Ali OH Hagelkruys A Stadlmann J Oostenbrink C Wirnsberger G Penninger JM Mirazimi A. 2021. Clinical grade ACE2 effectively inhibits SARS-CoV-2 Omicron infections. bioRxiv. https:\/\/www.biorxiv.org\/content\/10.1101\/2021.12.25.474113v1.","DOI":"10.1101\/2021.12.25.474113"},{"key":"e_1_3_2_94_2","doi-asserted-by":"crossref","unstructured":"Bojkova D Widera M Ciesek S Wass MN Michaelis M Cinatl J. 2022. Reduced interferon antagonism but similar drug sensitivity in Omicron variant compared to Delta variant SARS-CoV-2 isolates. bioRxiv. https:\/\/www.biorxiv.org\/content\/10.1101\/2022.01.03.474773v1.","DOI":"10.1101\/2022.01.03.474773"},{"key":"e_1_3_2_95_2","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2021.2023329"},{"key":"e_1_3_2_96_2","doi-asserted-by":"crossref","unstructured":"Willett BJ Grove J MacLean OA Wilkie C Logan N Lorenzo GD Furnon W Scott S Manali M Szemiel A Ashraf S Vink E Harvey W Davis C Orton R Hughes J Holland P Silva V Pascall D Puxty K da Filipe AS Yebra G Shaaban S Holden MTG Pinto RM Gunson R Templeton K Murcia P Patel AH The COVID-19 DeplOyed VaccinE (DOVE) Cohort Study investigators The COVID-19 Genomics UK (COG-UK) Consortium The G2P-UK National Virology Consortium The Evaluation of Variants Affecting Deployed COVID-19 Vaccines (EVADE) investigators Haughney J Robertson DL Palmarini M Ray S Thomson EC. 2022. The hyper-transmissible SARS-CoV-2 Omicron variant exhibits significant antigenic change vaccine escape and a switch in cell entry mechanism. medRxiv. https:\/\/www.medrxiv.org\/content\/10.1101\/2022.01.03.21268111v1.","DOI":"10.1101\/2022.01.03.21268111"},{"key":"e_1_3_2_97_2","doi-asserted-by":"publisher","DOI":"10.1002\/gch2.1018"},{"key":"e_1_3_2_98_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkw1065"},{"key":"e_1_3_2_99_2","doi-asserted-by":"publisher","DOI":"10.1038\/msb.2011.75"},{"key":"e_1_3_2_100_2","doi-asserted-by":"publisher","DOI":"10.3390\/v12091006"},{"key":"e_1_3_2_101_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27180-0"},{"key":"e_1_3_2_102_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2772-0"}],"container-title":["Journal of Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/jvi.02077-21","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/jvi.02077-21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T13:09:09Z","timestamp":1648040949000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/jvi.02077-21"}},"subtitle":[],"editor":[{"given":"Hector C.","family":"Aguilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,3,23]]},"references-count":101,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,3,23]]}},"alternative-id":["10.1128\/jvi.02077-21"],"URL":"https:\/\/doi.org\/10.1128\/jvi.02077-21","relation":{},"ISSN":["0022-538X","1098-5514"],"issn-type":[{"value":"0022-538X","type":"print"},{"value":"1098-5514","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,23]]},"assertion":[{"value":"2021-12-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02077-21"}}